000162191 001__ 162191
000162191 005__ 20251017144602.0
000162191 0247_ $$2doi$$a10.1016/j.vprsr.2020.100423
000162191 0248_ $$2sideral$$a118627
000162191 037__ $$aART-2020-118627
000162191 041__ $$aeng
000162191 100__ $$aGiner, J.
000162191 245__ $$aTreatment and follow-up of a domestic ferret (Mustela putorius furo) with clinical leishmaniosis caused by Leishmania infantum
000162191 260__ $$c2020
000162191 5060_ $$aAccess copy available to the general public$$fUnrestricted
000162191 5203_ $$aLeishmania infantum infection including treatment and follow up in domestic animals other than dogs and cats has not been described at this moment. This article describes the anti-Leishmania treatment and follow-up of a ferret (Mustela putorius furo) with leishmaniosis. A combined therapeutic protocol established for the patient, not yet approved for ferrets, was a combination of meglumine antimoniate plus allopurinol. A follow-up was established monthly during the first year in order to monitor the health condition of the patient. Six months after commencing allopurinol therapy, xanthine crystalluria was observed in urine sediment with no other urine alterations detected by urine analysis. The ferret worsened progressively with diarrhoea and weight loss after cohabiting with another ferret diagnosed with cryptosporidiosis. Cryptosporidium parvum was isolated in faecal samples from the patient detected by three different methods including Ziehl-Neelsen staining, a qualitative test to detection of C. parvum antigens and finally a specific molecular analysis to characterize the species. To the best of the authors´ knowledge, this is the first report providing information about anti-Leishmania protocol therapy used and follow-up in a domestic ferret with clinical leishmaniosis. Veterinarians practicing in endemic areas should be aware of this infection in ferrets at risk and their susceptibility especially when immunosuppressive conditions are present.
000162191 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc-nd$$uhttps://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
000162191 592__ $$a0.563$$b2020
000162191 593__ $$aVeterinary (miscellaneous)$$c2020$$dQ2
000162191 593__ $$aParasitology$$c2020$$dQ2
000162191 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/acceptedVersion
000162191 700__ $$0(orcid)0000-0001-6209-4282$$aVillanueva-Saz, S.$$uUniversidad de Zaragoza
000162191 700__ $$aAlcover, M.M.
000162191 700__ $$aRiera, C.
000162191 700__ $$aFisa, R.
000162191 700__ $$aBasurco, A.
000162191 700__ $$aYzuel, A.
000162191 700__ $$aTrotta, M.
000162191 700__ $$aFani, C.
000162191 700__ $$0(orcid)0000-0003-2957-1379$$aVerde, M.T.$$uUniversidad de Zaragoza
000162191 700__ $$0(orcid)0000-0002-2557-4890$$aFernández, A.$$uUniversidad de Zaragoza
000162191 7102_ $$11012$$2315$$aUniversidad de Zaragoza$$bDpto. Farmac.Fisiol.y Med.L.F.$$cÁrea Farmacología
000162191 7102_ $$11009$$2617$$aUniversidad de Zaragoza$$bDpto. Patología Animal$$cÁrea Medicina y Cirugía Animal
000162191 773__ $$g21 (2020), 100423 [9 pp.]$$tVeterinary Parasitology: Regional Studies and Reports$$x2405-9390
000162191 8564_ $$s1413277$$uhttps://zaguan.unizar.es/record/162191/files/texto_completo.pdf$$yPostprint
000162191 8564_ $$s941677$$uhttps://zaguan.unizar.es/record/162191/files/texto_completo.jpg?subformat=icon$$xicon$$yPostprint
000162191 909CO $$ooai:zaguan.unizar.es:162191$$particulos$$pdriver
000162191 951__ $$a2025-10-17-14:14:26
000162191 980__ $$aARTICLE